Management of adult patients with CMML ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Author(s) :
Onida, Francesco [Auteur]
Gagelmann, Nico [Auteur]
Chalandon, Yves [Auteur]
Kobbe, Guido [Auteur]
Robin, Marie [Auteur]
Université Paris Cité [UPCité]
Symeonidis, Argiris [Auteur]
De Witte, Theo [Auteur]
Itzykson, Raphael [Auteur]
Génomes, biologie cellulaire et thérapeutiques [GenCellDis (U944 / UMR7212)]
Jentzsch, Madlen [Auteur]
Platzbecker, Uwe [Auteur]
Santini, Valeria [Auteur]
Sanz, Guillermo [Auteur]
Scheid, Christof [Auteur]
Solary, Eric [Auteur]
Université Paris-Saclay
Valent, Peter [Auteur]
Greco, Raffaella [Auteur]
Sánchez-Ortega, Isabel [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Pleyer, Lisa [Auteur]
Gagelmann, Nico [Auteur]
Chalandon, Yves [Auteur]
Kobbe, Guido [Auteur]
Robin, Marie [Auteur]
Université Paris Cité [UPCité]
Symeonidis, Argiris [Auteur]
De Witte, Theo [Auteur]
Itzykson, Raphael [Auteur]
Génomes, biologie cellulaire et thérapeutiques [GenCellDis (U944 / UMR7212)]
Jentzsch, Madlen [Auteur]
Platzbecker, Uwe [Auteur]
Santini, Valeria [Auteur]
Sanz, Guillermo [Auteur]
Scheid, Christof [Auteur]
Solary, Eric [Auteur]
Université Paris-Saclay
Valent, Peter [Auteur]
Greco, Raffaella [Auteur]
Sánchez-Ortega, Isabel [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Pleyer, Lisa [Auteur]
Journal title :
Blood
Abbreviated title :
Blood
Volume number :
143
Pages :
2227–2244
Publication date :
2024-05-30
ISSN :
1528-0020
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially ...
Show more >Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.Show less >
Show more >Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-05-06T21:34:52Z
2024-08-20T12:54:17Z
2024-08-20T12:54:17Z